Search Results 291-300 of 17178 for egfr

  1. Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation - Mayo Clinic

    - Prior treatment with an anti-EGFR antibody (e.g., cetuximab or panitumumab). - Active brain metastasis. Note: Other protocol defined Inclusion/Exclusion ...

  2. A Phase 1/2 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway - Mayo Clinic

    SOS1, PTPN11, or EGFR mutation, or known annotated recurrent inactivating NF1 mutation; 2. MRTX0902 and adagrasib combination therapy: KRAS G12C mutation ...

  3. I-124 evuzamitide PET/CT Imaging for the Diagnosis of Cardiac Amyloidosis - Mayo Clinic

    eGFR less than 15ml/min/1.73m2. Myocardial infarction within three (3) months of screening. Has severe claustrophobia or any medical condition that would ...

  4. Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (SA-AKI) - Mayo Clinic

    eGFR \<45mL/min at admission without any other reference serum eGFR within last 12-months 5. Receiving RRT or a decision has been made to initiate RRT ...

  5. Breast MR - Mayo Clinic

    eGFR ≤ 30 (4,5). History of prior moderate or severe contrast reaction including unresponsiveness, severe respiratory distress, convulsions, arrhythmia ...

  6. Clinical trials - Oncology (Medical)

    ... (eGFR ≥ 60ml/min). Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies. Scottsdale/Phoenix, Ariz. The ...

  7. Focal segmental glomerulosclerosis: Understanding a rare kidney disease - Mayo Clinic

    Other glomerular diseases include IgA nephropathy and complement 3 glomerulopathy. FSGS happens when the glomeruli harden or develop scar tissue. The term “ ...

  8. Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis - Mayo Clinic

    * eGFR ≥ 25mL/min/1.73 m2. Participants with eGFR \< 30 mL/min/1.73 m2 require renal biopsy during the screening period showing sclerosis in ≤ 50% of ...

  9. Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024) - Mayo Clinic

    EGFR sensitizing mutation and/or ALK translocation; Currently participating or has participated in a study of an investigational agent or using an ...

  10. Pilot Study of Rituximab to Treat Fibrillary Glomerulonephritis - Mayo Clinic

    eGFR greater than or equal to 25 mL/ min using CKD EPI formula or a quantified creatinine clearance > 25mL/ min and/or serum creatinine <3.0 mg/dL; Negative ...